ImmuCell Statistics
Total Valuation
ImmuCell has a market cap or net worth of $27.65 million. The enterprise value is $42.16 million.
Important Dates
The next confirmed earnings date is Wednesday, November 13, 2024, after market close.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ImmuCell has 7.83 million shares outstanding. The number of shares has increased by 0.23% in one year.
| Current Share Class | 7.83M |
| Shares Outstanding | 7.83M |
| Shares Change (YoY) | +0.23% |
| Shares Change (QoQ) | +0.76% |
| Owned by Insiders (%) | 33.42% |
| Owned by Institutions (%) | 14.48% |
| Float | 4.71M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.18 |
| Forward PS | n/a |
| PB Ratio | 1.18 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.82 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.37, with a Debt / Equity ratio of 0.68.
| Current Ratio | 2.37 |
| Quick Ratio | 0.72 |
| Debt / Equity | 0.68 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.72 |
Financial Efficiency
Return on equity (ROE) is -16.10% and return on invested capital (ROIC) is -5.15%.
| Return on Equity (ROE) | -16.10% |
| Return on Assets (ROA) | -4.87% |
| Return on Capital (ROIC) | -5.15% |
| Revenue Per Employee | $293,961 |
| Profits Per Employee | -$51,257 |
| Employee Count | 79 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 2.24 |
Taxes
In the past 12 months, ImmuCell has paid $4,257 in taxes.
| Income Tax | 4,257 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -31.72% in the last 52 weeks. The beta is 0.57, so ImmuCell's price volatility has been lower than the market average.
| Beta (5Y) | 0.57 |
| 52-Week Price Change | -31.72% |
| 50-Day Moving Average | 3.66 |
| 200-Day Moving Average | 4.44 |
| Relative Strength Index (RSI) | 43.91 |
| Average Volume (20 Days) | 16,631 |
Short Selling Information
The latest short interest is 8,184, so 0.10% of the outstanding shares have been sold short.
| Short Interest | 8,184 |
| Short Previous Month | 11,659 |
| Short % of Shares Out | 0.10% |
| Short % of Float | 0.17% |
| Short Ratio (days to cover) | 0.29 |
Income Statement
In the last 12 months, ImmuCell had revenue of $23.22 million and -$4.05 million in losses. Loss per share was -$0.52.
| Revenue | 23.22M |
| Gross Profit | 6.58M |
| Operating Income | -3.35M |
| Pretax Income | -3.89M |
| Net Income | -4.05M |
| EBITDA | -633,697 |
| EBIT | -3.35M |
| Loss Per Share | -$0.52 |
Full Income StatementBalance Sheet
The company has $1.32 million in cash and $15.84 million in debt, giving a net cash position of -$14.51 million or -$1.85 per share.
| Cash & Cash Equivalents | 1.32M |
| Total Debt | 15.84M |
| Net Cash | -14.51M |
| Net Cash Per Share | -$1.85 |
| Equity (Book Value) | 23.46M |
| Book Value Per Share | 2.99 |
| Working Capital | 6.24M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$230,540 and capital expenditures -$682,956, giving a free cash flow of -$913,496.
| Operating Cash Flow | -230,540 |
| Capital Expenditures | -682,956 |
| Free Cash Flow | -913,496 |
| FCF Per Share | -$0.12 |
Full Cash Flow StatementMargins
Gross margin is 28.32%, with operating and profit margins of -14.41% and -17.44%.
| Gross Margin | 28.32% |
| Operating Margin | -14.41% |
| Pretax Margin | -17.42% |
| Profit Margin | -17.44% |
| EBITDA Margin | -2.73% |
| EBIT Margin | -14.41% |
| FCF Margin | -13.02% |